Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rangering i aksjer #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Aksjekurs
$5.47
Sist synkronisert: 2026-08-14
Markedsverdi
$7.99M
Endring (1 dag)
6.21%
Endring (1 år)
7.47%
Land
US
Handel CNS Pharmaceuticals, Inc. (CNSP)

Kategori

Aksjeprishistorikk for CNS Pharmaceuticals, Inc. (CNSP)
Høyeste sluttskurs: $5.27 den 2026-08-01

Laveste sluttskurs: $3.79M den 2019-11-01
Aksjeprishistorikk for CNS Pharmaceuticals, Inc. fra 2019 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) -16.52%
2025 -89.84%
2024 -99.87%
2023 -34.43%
2022 -90.86%
2021 -58.90%
2020 -43.49%
2019 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$505.24 28.63%
US
$846.09 29.41%
NL
$735.86 7.08%
CH
$1.07K -6.40%
KR
$255.26 13.28%
BE